Clinical Trials in Tennessee

Showing 2321-2340 of 9,675 trials

Real-World Evidence on the Cardiovascular Safety of CONTRAVE® in the United States (U.S.)

NCT06090461

The fixed-dose combination of naltrexone 8mg and bupropion 90mg extended-release oral tablet is marketed under the trade name CONTRAVE® in the U.S. In this protocol, the investigators propose to generate real-world evidence (RWE) from electronic health records (EHR) and linked claims data to assess the cardiovascular safety of CONTRAVE® and all combined use of naltrexone and bupropion (NB) in usual clinical practice.

Obesity

Currax Pharmaceuticals31,889 participantsStarted Sep 2014

Brentwood, Tennessee, United States

COMPLETEDPhase 129 miles

Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules

NCT01226316

This study is designed to investigate the safety and tolerability of a new drug, AZD5363, in patients with advanced cancer - and to identify a dose and schedule that can be used in the future. This study will also investigate how the body handles AZD5363 (ie, how quickly the body absorbs and removes the drug). This study will also investigate anti-tumour activity of AZD5363 in patients with advanced / metastatic breast, gynaecological cancers or other solid cancers bearing either AKT1 / PIK3CA or PTEN mutation.

Advanced Solid MalignancySafety and TolerabilityPharmacokinetics+11 more

AstraZeneca285 participantsStarted Dec 2010

Los Angeles, California, United States • Stanford, California, United States • West Hollywood, California, United States +31 more locations

Real-World Evidence on the Cardiovascular Safety of CONTRAVE® in the United States (U.S.)

Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules

Find Trials by Condition in Tennessee

Gluten Technology and Education for Celiac Health

Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations

DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors

Paclitaxel Coated Balloon for the Treatment of Chronic bEnigN sTricture- Bowel

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of GSK5733584 for Injection in Participants With Advanced Solid Tumors

Attentional Mechanisms in SCD

Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥6 Months to <18 Years of Age With Atopic Dermatitis (AD)

Optimizing the Use of Ketamine to Reduce Chronic Postsurgical Pain

Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma

Trial to Evaluate the Safety and Pharmacokinetics of HMPL-689 in Patients With Lymphomas

Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized With NFKB2 Rearrangement

The Biomarkers in the Hyperbaric Oxygen Brain Injury Treatment Trial (BioHOBIT)

A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma

Proliposomal Intravesical Paclitaxel for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder Cancer

1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation

A Study of NPX887 for Participants With Solid Tumors Known to Express B7-H7/HHLA2

FS120 Phase 1/1b Study in Patients With Advanced Malignancies

Cough Reduction in IPF With Nalbuphine ER